Editorial: Response to “The Cure” by Geeta Anand

Sep 2, 2006 | EDITORIALS

By: Marylyn House posted on: September 02, 2006 (this response was written based on an expert found on Amazon.com and an article in the Wall Street Journal) Dear All, The following excerpt from Geeta Anand’s “story” on John Crowley can be found in the “Marketplace”...

Letter From IPA and Genzyme Concerning LOTS

Jun 8, 2006 | NEWS

Dear IPA members, Pompe patients, family members and GSD-net participants, The IPA board received several questions concerning participation in the LOTS trial. As there are certain restrictions to the market approval of MyozymeA form of enzyme replacement therapy used...

European Commission Approves Genzyme’s Myozyme®

Apr 4, 2006 | NEWS

Product is First Treatment for Pompe Disease Genzyme Corp. (Nasdaq: GENZ) announced today that it has received marketing authorization for Myozyme® (alglucosidase alfa) in the European Union. Myozyme has been approved for long-term enzyme replacement therapy in...

Genzyme Provides Update on U.S. Marketing Application for Myozyme

Jan 18, 2006 | NEWS

Genzyme Corp. (Nasdaq: GENZ) announced today that the Food and Drug Administration has extended by 90 days the review period for the biologics license application for Myozyme® (alglucosidase alfa). The new action date for the application is April 28, 2006. The purpose...

The IPA Pompe Connections Brochure

Oct 2, 2005 | NEWS

The IPA has developed the Pompe connections brochure to help get patients and their families timely and relevant information about Pompe disease and the developments that are happening. Please visit the Pompe Connections Brochure page.

Genzyme Submits BLA for Myozyme® for Treatment of Pompe Disease

Jul 30, 2005 | NEWS

Genzyme Corp. (Nasdaq: GENZ) announced today that it has submitted a biologics license application (BLA) to the U.S. Food and Drug Administration for Myozyme® (alglucosidase alfa). If approved, Myozyme would be the first treatment developed for patients with Pompe...

Summary of the 2005 AFM-IPA Conference

May 13, 2005 | NEWS

May 11th 2005 IPA Conference Pompe’s disease Nantes, France. “Emerging therapies for Pompe disease” Dr. Ans van der Ploeg, Erasmus MC Rotterdam the Netherlands, talked about the natural course in late onset Pompe disease. She informed the audience about the outcome...

Genzyme Reports Interim Results from Pivotal Study of Myozyme

Apr 26, 2005 | NEWS

CAMBRIDGE, Mass.—Genzyme Corp. (Nasdaq: GENZ) announced today that it has completed a planned analysis of interim data from its pivotal clinical trial of Myozyme® (alglucosidase alfa), which is being studied for the treatment of Pompe disease. The interim analysis was...